Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

NCT02326220 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

DRUG: Placebo
DRUG: Alirocumab

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]